Portola Pharmaceuticals Announces Upcoming Data Presentations on Betrixaban and Andexanet Alfa at the International Society o...
06 Juillet 2017 - 2:00PM
Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced
that data on betrixaban and andexanet alfa, as well as
presentations on disease awareness and risk, would be presented at
the International Society on Thrombosis and Haemostasis (ISTH)
annual meeting, which is taking place from July 8-13 in Berlin,
Germany. Details regarding the presentations follow.
Oral Presentation Details:
- Presentation Title: Prevention of
Exsanguination under Apixaban Anticoagulation Using Andexanet Alfa
in a Polytrauma Model
- Presenter: Oliver Grottke, M.D., Ph.D., RWTH
University Hospital Aachen
- Session Title: Bleeding Management Under Oral
Anticoagulation
- Presentation Date and Time: July 10, 2017 from
2:45-4:15 p.m. UTC
- Session Room: London
- Presentation Title: Prevalence of Major
Medical Illnesses Associated with Venous Thromboembolism Risk in US
Hospitals
- Presenter: Alexander Cohen, MBBS, M.Sc., M.D.,
King’s College London
- Session Title: DOACs and Beyond: Translational
Aspects
- Presentation Date and Time: July 13, 2017 from
9:30-10:45 a.m. UTC
- Session Room: Berlin
- Presentation Title: A Landmark Analysis of the
APEX Study Comparing Extended Duration Betrixaban with Standard
Duration Enoxaparin in Hospitalized Medically Ill Patients
- Presenter: Alexander Cohen, MBBS, M.Sc., M.D.,
King’s College London
- Session Title: Advances in
Thromboprophylaxis
- Presentation Date and Time: July 12, 2017 from
9:45-10:45 a.m. UTC
- Location: Hall B
- Presentation Title: Pharmacokinetic and
Pharmacodynamic Modeling of Andexanet Alfa Dose to Reverse the
Anticoagulant Activity of FXa Inhibitors in Patients with Acute
Major Bleeding
- Presenter: Janet Leeds, Ph.D., Portola
Pharmaceuticals
- Session Title: DOACs and Beyond: Translational
Aspects
- Presentation Date and Time: July 13, 2017 from
9:30-10:45 a.m. UTC
- Session Room: Berlin
Poster Presentation Details:
- Presentation Title: A Cross-Sectional,
Multinational, Multidisciplinary Survey of Physicians Surrounding
the Management of Bleeding Complications in the Setting of Direct
Oral Anticoagulant Use
- Presenter: Joseph Shaw, M.D., BSc, University
of Ottawa
- Poster Number: PB 472
- Presentation Date and Time: July 10, 2017 from
12:00-1:15 p.m. UTC
- Location: Exhibition Hall 2.2
- Presentation Title: Impact of Evolving ACCP
Guidelines on Estimates of Venous Thromboembolism Risk in US
Hospitals
- Presenter: Alexander Cohen, MBBS, M.Sc., M.D.,
King’s College London and Frederick Anderson, Jr., Ph.D.,
University of Massachusetts Medical School
- Poster Number: PB 1193
- Presentation Date and Time: July 11, 2017 from
12:00-1:15 p.m. UTC
- Location: Exhibition Hall 4.2
- Presentation Title: D-dimer in Acute Medically
Ill Adults and Current Thromboprophylaxis: A Multicenter
Observational Study Evaluating the Prevalence of Elevated D-dimer
in Acute Medically Ill, Hospitalized Adults and Current
Thromboprophylaxis Trends; the DAMIACT Study, Initial Data
Analysis
- Presenter: Richey Neuman, M.D., M.P.H.,
F.A.C.P., Portola Pharmaceuticals
- Poster Number: PB 1416
- Presentation Date and Time: July 11, 2017 from
12:00-1:15 p.m. UTC
- Location: Exhibition Hall 6.2
About Portola Pharmaceuticals,
Inc. Portola Pharmaceuticals is a biopharmaceutical
company developing product candidates that could significantly
advance the fields of thrombosis and other hematologic diseases.
The Company’s first medicine Bevyxxa®
(betrixaban), an oral, once-daily Factor Xa inhibitor, was approved
by the U.S. Food and Drug Administration in June 2017. The company
is also working to advance two clinical programs for andexanet
alfa, a recombinant protein designed to reverse the anticoagulant
effect in patients treated with an oral or injectable Factor Xa
inhibitor; and cerdulatinib, a SYK/JAK inhibitor in development to
treat hematologic cancers. Portola's partnered program is focused
on developing selective SYK inhibitors for inflammatory conditions.
For more information, visit http://www.portola.com and follow
the Company on Twitter @Portola_Pharma.
Investor Contact:
Mardi Dier
Portola Pharmaceuticals
mdier@portola.com
Media Contact:
Julie Normart
Pure Communications
jnormart@purecommunications.com
415.946.1087
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Portola Pharmaceuticals Inc (NASDAQ): 0 recent articles
Plus d'articles sur